(Q44594055)
Statements
Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy (English)
Erica Dearstyne
Yukang Lin
Yuting Zuo
James Sanderson
Jody Schultz
Anastasia Pantalias
David Gray
Don Axworthy
Karen Auditore-Hargreaves
Scott S. Graves
1 September 2003